Research Analysts Issue Forecasts for WVE FY2025 Earnings

Key Points

• Equities research analysts at HC Wainwright have revised their FY2025 EPS estimates for WAVE Life Sciences from ($0.92) to ($0.97), with a consensus expectation of ($1.14) per share for the year.
• Despite the lowered earnings forecast, WAVE Life Sciences has a consensus rating of "Moderate Buy" from analysts, with an average target price of $20.36 per share.
• Insider trading activities showed that Director Gregory L. Verdine sold 30,000 shares, decreasing their position by 9.60%, while company insiders collectively own 23.98% of the stock.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of WAVE Life Sciences in a report released on Thursday, July 31st. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.97) for the year, down from their prior forecast of ($0.92). The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences' FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.72 EPS.

WVE has been the subject of a number of other reports. Citigroup assumed coverage on shares of WAVE Life Sciences in a research report on Wednesday, July 16th. They set a "buy" rating and a $16.00 price objective for the company. Raymond James Financial assumed coverage on WAVE Life Sciences in a report on Wednesday, June 11th. They set an "outperform" rating and a $14.00 target price for the company. Wedbush reissued an "outperform" rating and set a $18.00 target price on shares of WAVE Life Sciences in a report on Monday, June 23rd. Oppenheimer initiated coverage on WAVE Life Sciences in a research note on Monday, July 28th. They issued an "outperform" rating and a $24.00 price target for the company. Finally, Wells Fargo & Company dropped their price target on WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, WAVE Life Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $20.36.

WAVE Life Sciences Stock Up 6.5%

Shares of WVE opened at $8.63 on Monday. The stock has a market capitalization of $1.37 billion, a P/E ratio of -9.59 and a beta of -0.95. WAVE Life Sciences has a twelve month low of $5.04 and a twelve month high of $16.74. The company has a 50 day moving average of $7.22 and a 200-day moving average of $8.27.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The business had revenue of $8.70 million for the quarter, compared to analysts' expectations of $11.52 million.

Insider Buying and Selling at WAVE Life Sciences

In related news, Director Gregory L. Verdine sold 30,000 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $6.95, for a total transaction of $208,500.00. Following the transaction, the director directly owned 282,517 shares of the company's stock, valued at approximately $1,963,493.15. This trade represents a 9.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 23.98% of the company's stock.

Hedge Funds Weigh In On WAVE Life Sciences

A number of large investors have recently bought and sold shares of WVE. GF Fund Management CO. LTD. bought a new stake in shares of WAVE Life Sciences during the fourth quarter valued at approximately $40,000. Quarry LP bought a new stake in shares of WAVE Life Sciences during the fourth quarter valued at approximately $62,000. Summit Investment Advisors Inc. boosted its position in shares of WAVE Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock valued at $119,000 after purchasing an additional 2,308 shares in the last quarter. Westwood Wealth Management bought a new stake in shares of WAVE Life Sciences during the fourth quarter valued at approximately $124,000. Finally, Knott David M Jr bought a new stake in shares of WAVE Life Sciences during the first quarter valued at approximately $81,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.